Latest news with #POLAR
Business Wire
08-08-2025
- Business
- Business Wire
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2025. 'We remain focused on exploring strategic alternatives and partnerships across our portfolio to enhance long-term shareholder value, as exemplified by our recent worldwide licensing agreement with Debiopharm for lunresertib and out-licensing of early-stage discovery platforms to DCx,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'In parallel to evaluating these strategic opportunities for our remaining programs, we expect to deliver initial data from the LIONS and POLAR trials in the fourth quarter.' Second Quarter 2025 and Recent Portfolio Highlights: Entered into a worldwide licensing agreement with Debiopharm for lunresertib In July 2025, Repare entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ('Debiopharm') for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. This agreement builds on the success of Repare and Debiopharm's clinical study and collaboration agreement to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib. Announced out-licensing of its discovery platforms to DCx Biotherapeutics In May 2025, Repare out-licensed its early-stage discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ('DCx'), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates supported by Amplitude Ventures. In connection with this agreement, Repare received a $1 million upfront payment and is expected to receive $3 million in near-term payments. In addition, Repare received a 9.99% equity position in DCx, including certain dilution protection rights, and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low single-digit sales royalties for the development of certain products by DCx. In connection with this transaction, Repare recognized a $5.7 million gain during the quarter. RP-3467: Potential best-in-class, oral Polθ ATPase/helicase inhibitor Repare is conducting a Phase 1 clinical trial of RP-3467 (POLAR), dosing patients alone and in combination with the poly-ADP ribose polymerase (PARP) inhibitor, olaparib. POLAR is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3647 alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Upcoming expected milestone: Q4 2025: Topline safety, tolerability and early efficacy data from the POLAR trial in monotherapy and in combination with olaparib. RP-1664: First-in-class, oral selective PLK4 Inhibitor Repare completed enrolment of 29 patients in its Phase 1 LIONS clinical trial, evaluating RP-1664 as a monotherapy in adult and adolescent patients with TRIM37-high solid tumors. LIONS is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664. Upcoming expected milestone: Amended our collaboration and license agreement with Bristol-Myers Squibb Company to include an additional druggable target in the collaboration Repare recognized $0.3 million during the quarter as revenue related to druggable targets, reflecting this option fee payment. Exploring strategic alternatives to maximize shareholder value Repare continues to actively explore strategic alternatives, partnerships and sale opportunities across its portfolio to maximize shareholder value. Second Quarter 2025 Financial Results Cash, cash equivalents and marketable securities: Cash, cash equivalents and marketable securities as of June 30, 2025 were $109.5 million. Revenue from collaboration agreements: Revenue from collaboration agreements were $0.3 million for the three and six months ended June 30, 2025, respectively, as compared $1.1 million and $53.5 million for three and six months ended June 30, 2024. Research and development expense, net of tax credits (Net R&D): Net R&D expenses were $14.3 million and $34.6 million for the three and six months ended June 30, 2025, respectively, as compared to $30.1 million and $63.1 for the three and six months ended June 30, 2024. General and administrative (G&D) expenses: G&A expenses were $6.0 million and $13.7 million for the three and six months ended June 30, 2025, respectively, compared to $8.3 million and $16.9 million for the three and six months ended June 30, 2024. Net loss: Net loss was $16.7 million, or $0.39 per share, and $46.8 million, or $1.09 per share, in the three and six months ended June 30, 2025, respectively, compared to $34.8 million, or $0.82 per share, and $21.6 million, or $0.51 per share, in the three and six months ended June 30, 2024, respectively. About Repare Therapeutics Inc. Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's licensing arrangements with Debiopharm and DCx, including the potential benefits of such transactions and the receipt of clinical and commercial milestone payments and royalties under such agreements; the Company's plans for exploring strategic alternatives and partnerships across the clinical portfolio; and the design, objectives, initiation, timing, progress and results of current and future clinical trials of the Company's product candidates including the advancement of its two ongoing clinical trials. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company's ability to successfully pursue a strategic transaction on attractive terms, or at all; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ('AMF') on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at Repare Therapeutics Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Amounts in thousands of U.S. dollars, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenue: Collaboration agreements $ 250 $ 1,073 $ 250 $ 53,477 Operating expenses: Research and development, net of tax credits 14,283 30,075 34,553 63,045 General and administrative 6,029 8,317 13,681 16,935 Restructuring 3,384 — 6,649 — Total operating expenses 23,696 38,392 54,883 79,980 Gain on sale of technology and other assets 5,666 — 5,666 — Loss from operations (17,780 ) (37,319 ) (48,967 ) (26,503 ) Other income (expense), net Realized and unrealized gain on foreign exchange 66 6 64 37 Interest income 1,236 2,894 2,774 5,862 Other expense, net (18 ) (29 ) (40 ) (53 ) Total other income, net 1,284 2,871 2,798 5,846 Loss before income taxes (16,496 ) (34,448 ) (46,169 ) (20,657 ) Income tax expense (248 ) (326 ) (618 ) (955 ) Net loss $ (16,744 ) $ (34,774 ) $ (46,787 ) $ (21,612 ) Other comprehensive loss: Unrealized loss on available-for-sale marketable securities $ (17 ) $ (21 ) $ (62 ) $ (162 ) Total other comprehensive loss (17 ) (21 ) (62 ) (162 ) Comprehensive loss $ (16,761 ) $ (34,795 ) $ (46,849 ) $ (21,774 ) Net loss per share attributable to common shareholders - basic and diluted $ (0.39 ) $ (0.82 ) $ (1.09 ) $ (0.51 ) Weighted-average common shares outstanding - basic and diluted 42,921,936 42,445,462 42,757,745 42,339,732 Expand
Business Wire
16-07-2025
- Business
- Business Wire
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ('Debiopharm'), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. 'The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm's existing collaboration studying the combination of lunresertib and Debio 0123,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation. We remain focused on two ongoing Phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor.' Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib. 'We are excited to enter into this worldwide license agreement with Repare for lunresertib. Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,' said Bertrand Ducrey, CEO of Debiopharm. 'We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult to treat cancers.' Continued Prioritization of RP-3467 and RP-1664 Moving forward, Repare will remain focused on the advancement of its two ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Polθ) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations, alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 alone and in combination with olaparib is expected in the third quarter of 2025. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 is expected in the fourth quarter of 2025. About Repare Therapeutics Inc. Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Debiopharm's Commitment to Patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit Follow us, we are on LinkedIn. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of lunresertib to Debiopharm, including the potential benefits of the transaction and the achievement and receipt of milestone payments and royalties under the license agreement; the Company's anticipated cash runway; the timing, progress and results of the Company's ongoing Phase 1 LIONS and POLAR clinical trials; and the potential, tolerability, efficacy and clinical progress of the Company's product candidates, including the potential of lunresertib to treat patients with difficult-to-treat solid tumors as a monotherapy or in combination with Debio 0123. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ("AMF") on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at
Economic Times
02-06-2025
- Entertainment
- Economic Times
Wordle hints and answer for June 2, 2025: Today's #1444 hints, clues, rare letter trick, and winning strategy to solve the puzzle fast
Wordle Hints, Answer and Help for June 2 offers players a simple, clue-by-clue breakdown of puzzle #1444. If you're stuck or just curious, this guide reveals all — including the final answer and the logic behind it. With hints about repeated vowels and letter placement, plus insight into past Wordle answers like ROUGH, IDIOM, and QUASH, this article helps you decode patterns and improve your strategy. Also includes updates on NYT puzzles like Connections and Strands. If you love Wordle or just want to win more often, this story makes it easy to follow and fun to read. Stuck on today's Wordle puzzle? Find June 2 Wordle hints, final answer, strategy tips, and NYT puzzle help all in one place. Decode Wordle #1444 now and never miss a win. Also includes answers for Connections and Strands. Tired of too many ads? Remove Ads What is the Wordle hint about repeated letters? How many vowels are in today's Wordle answer? Which letter does today's Wordle start with? Tired of too many ads? Remove Ads What kind of action does today's answer describe? So, what is today's Wordle answer for June 2? What was yesterday's Wordle answer? What were the most recent Wordle answers this week? May 28 (#1439): POLAR May 29 (#1440): QUASH May 30 (#1441): IDIOM May 31 (#1442): HABIT June 1 (#1443): ROUGH June 2 (#1444): PREEN Why is Wordle still so popular in 2025? On today's Wordle and what to expect tomorrow Tired of too many ads? Remove Ads FAQs: If you're hunting for today's Wordle hints , answer and help for June 2, you're in the right place. Whether you're stuck on the puzzle or just want to see how today's Wordle compares to yesterday's, we've broken down everything — hints, clues, and the final answer — in a simple and conversational 2's Wordle puzzle (#1444) stumped a fair number of players due to its tricky letter placement and less common structure. The answer features a repeated vowel and starts with a letter that isn't usually your first guess. If that threw you off, don't worry — we've got your of the first things to know about today's puzzle is that it includes a repeated letter — and in this case, that repeated letter is a vowel. So if you tried to guess words with lots of different vowels, this might have led you off there's just one vowel in today's answer — and it shows up twice. This detail alone should give a major clue, especially if you're narrowing down your guesses after the second or third answer begins with the letter P, which isn't always a top choice for opening guesses. But in this puzzle, P sets the tone for the rest of the word — and leads you closer to something you've probably heard in the context of birds or a big giveaway: the word is often used when talking about birds, especially when they're smoothing out or cleaning their feathers. But it's also used by humans, especially in terms of getting ready or perfecting one's appearance. It's a word that blends nature and vanity — quite Wordle answer for June 2, 2025, Puzzle #1444 is:If you guessed it, well done! If not, now you've got a new word to remember — and maybe use in your everyday conversations. 'He preened before heading out,' or 'The bird preened its feathers after flying.'In case you missed it, the answer for June 1 (Puzzle #1443) was ROUGH. It's a much more common word, so many players found it easier compared to today's more nuanced a quick recap of recent puzzles if you're tracking patterns or just curious:Despite being years old, Wordle remains one of the most played daily puzzle games globally. Thanks to its simplicity — one puzzle a day, six guesses — and social media shareability, it continues to dominate morning routines and coffee break chats. Owned by The New York Times, it now sits alongside other trending puzzles like Connections, Strands, and The Mini Crossword, which also see daily word — PREEN — was definitely on the trickier side, especially with its repeated vowel and less common usage in everyday conversation. But that's part of the charm with Wordle: it surprises you just when you think you've got the strategy nailed an eye out for tomorrow's puzzle and remember to start with a strong opener — words like SLATE, CRANE, or STARE often give a solid mix of vowels and common consonants.A1: The Wordle answer for June 2 isA2: You can get full hints, answers, and help for, andin the same article.
Time of India
02-06-2025
- Entertainment
- Time of India
Wordle hints and answer for June 2, 2025: Today's #1444 hints, clues, rare letter trick, and winning strategy to solve the puzzle fast
Wordle Hints, Answer and Help for June 2 offers players a simple, clue-by-clue breakdown of puzzle #1444. If you're stuck or just curious, this guide reveals all — including the final answer and the logic behind it. With hints about repeated vowels and letter placement, plus insight into past Wordle answers like ROUGH, IDIOM, and QUASH, this article helps you decode patterns and improve your strategy. Also includes updates on NYT puzzles like Connections and Strands. If you love Wordle or just want to win more often, this story makes it easy to follow and fun to read. Stuck on today's Wordle puzzle? Find June 2 Wordle hints, final answer, strategy tips, and NYT puzzle help all in one place. Decode Wordle #1444 now and never miss a win. Also includes answers for Connections and Strands. Tired of too many ads? Remove Ads What is the Wordle hint about repeated letters? How many vowels are in today's Wordle answer? Which letter does today's Wordle start with? Tired of too many ads? Remove Ads What kind of action does today's answer describe? So, what is today's Wordle answer for June 2? What was yesterday's Wordle answer? What were the most recent Wordle answers this week? May 28 (#1439): POLAR May 29 (#1440): QUASH May 30 (#1441): IDIOM May 31 (#1442): HABIT June 1 (#1443): ROUGH June 2 (#1444): PREEN Why is Wordle still so popular in 2025? On today's Wordle and what to expect tomorrow Tired of too many ads? Remove Ads FAQs: If you're hunting for today's Wordle hints , answer and help for June 2, you're in the right place. Whether you're stuck on the puzzle or just want to see how today's Wordle compares to yesterday's, we've broken down everything — hints, clues, and the final answer — in a simple and conversational 2's Wordle puzzle (#1444) stumped a fair number of players due to its tricky letter placement and less common structure. The answer features a repeated vowel and starts with a letter that isn't usually your first guess. If that threw you off, don't worry — we've got your of the first things to know about today's puzzle is that it includes a repeated letter — and in this case, that repeated letter is a vowel. So if you tried to guess words with lots of different vowels, this might have led you off there's just one vowel in today's answer — and it shows up twice. This detail alone should give a major clue, especially if you're narrowing down your guesses after the second or third answer begins with the letter P, which isn't always a top choice for opening guesses. But in this puzzle, P sets the tone for the rest of the word — and leads you closer to something you've probably heard in the context of birds or a big giveaway: the word is often used when talking about birds, especially when they're smoothing out or cleaning their feathers. But it's also used by humans, especially in terms of getting ready or perfecting one's appearance. It's a word that blends nature and vanity — quite Wordle answer for June 2, 2025, Puzzle #1444 is:If you guessed it, well done! If not, now you've got a new word to remember — and maybe use in your everyday conversations. 'He preened before heading out,' or 'The bird preened its feathers after flying.'In case you missed it, the answer for June 1 (Puzzle #1443) was ROUGH. It's a much more common word, so many players found it easier compared to today's more nuanced a quick recap of recent puzzles if you're tracking patterns or just curious:Despite being years old, Wordle remains one of the most played daily puzzle games globally. Thanks to its simplicity — one puzzle a day, six guesses — and social media shareability, it continues to dominate morning routines and coffee break chats. Owned by The New York Times, it now sits alongside other trending puzzles like Connections, Strands, and The Mini Crossword, which also see daily word — PREEN — was definitely on the trickier side, especially with its repeated vowel and less common usage in everyday conversation. But that's part of the charm with Wordle: it surprises you just when you think you've got the strategy nailed an eye out for tomorrow's puzzle and remember to start with a strong opener — words like SLATE, CRANE, or STARE often give a solid mix of vowels and common consonants.A1: The Wordle answer for June 2 isA2: You can get full hints, answers, and help for, andin the same article.
Yahoo
02-06-2025
- Entertainment
- Yahoo
Wordle hints today for #1,444: Clues and answer for Monday, June 2
Hey, there! Welcome to the start of a new week. We hope you're well-rested, feeling energized and ready to keep your Wordle streak rolling for as long as possible. In case you'd like some assistance with that, here's our daily Wordle guide with some hints and the answer for Monday's puzzle (#1,444). It may be that you're a Wordle newcomer and you're not completely sure how to play the game. We're here to help with that too. Wordle is a deceptively simple daily word game that first emerged in 2021. The gist is that there is one five-letter word to deduce every day by process of elimination. The daily word is the same for everyone. Wordle blew up in popularity in late 2021 after creator Josh Wardle made it easy for players to share an emoji-based grid with their friends and followers that detailed how they fared each day. The game's success spurred dozens of clones across a swathe of categories and formats. The New York Times purchased Wordle in early 2022 for an undisclosed sum. The publication said that players collectively played Wordle 5.3 billion times in 2024. So, it's little surprise that Wordle is one of the best online games and puzzles you can play daily. To start playing Wordle, you simply need to enter one five-letter word. The game will tell you how close you are to that day's secret word by highlighting letters that are in the correct position in green. Letters that appear in the word but aren't in the right spot will be highlighted in yellow. If you guess any letters that are not in the secret word, the game will gray those out on the virtual keyboard. However, you can still use those letters in subsequent guesses. You'll only have six guesses to find each day's word, though you still can use grayed-out letters to help narrow things down. It's also worth remembering that letters can appear in the secret word more than once. Wordle is free to play on the NYT's website and apps, as well as on Meta Quest headsets. The game refreshes at midnight local time. If you log into a New York Times account, you can track your stats, including the all-important win streak. If you have a NYT subscription that includes full access to the publication's games, you don't have to stop after a single round of Wordle. You'll have access to an archive of more than 1,400 previous Wordle games. So if you're a relative newcomer, you'll be able to go back and catch up on previous editions. In addition, paid NYT Games members have access to a tool called the Wordle Bot. This can tell you how well you performed at each day's game. Before today's Wordle hints, here are the answers to recent puzzles that you may have missed: Yesterday's Wordle answer for Sunday, June 1 — ROUGH Saturday, May 31 — HABIT Friday, May 30 — IDIOM Thursday, May 29 — QUASH Wednesday, May 28 — POLAR Every day, we'll try to make Wordle a little easier for you. First, we'll offer a hint that describes the meaning of the word or how it might be used in a phrase or sentence. We'll also tell you if there are any double (or even triple) letters in the word. In case you still haven't quite figured it out by that point, we'll then provide the first letter of the word. Those who are still stumped after that can continue on to find out the answer for today's Wordle. This should go without saying, but make sure to scroll slowly. Spoilers are ahead. Here is a hint for today's Wordle answer: Gloat. Also, what a bird does to groom itself with its beak. There is a pair of repeated letters in today's Wordle answer. The first letter of today's Wordle answer is P. This is your final warning before we reveal today's Wordle answer. No take-backs. Don't blame us if you happen to scroll too far and accidentally spoil the game for yourself. What is today's Wordle? Today's Wordle answer is... PREEN Not to worry if you didn't figure out today's Wordle word. If you made it this far down the page, hopefully you at least kept your streak going. And, hey: there's always another game tomorrow.
